Document Detail

Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression.
MedLine Citation:
PMID:  23252945     Owner:  NLM     Status:  MEDLINE    
AIM: To investigate whether idarubicin in a cytarabine-based induction regimen was superior to daunorubicin in de novo acute myeloid leukemia patients expressing high MDR1.
PATIENTS & METHODS: The clinicopathological data were analyzed in 125 patients receiving daunorubicin or idarubicin with cytarabine for remission induction. Median MDR1 mRNA expression in pretreated bone marrow cells was used as the cutoff point for high and low MDR1 expression.
RESULTS: A total of 59.7% high and 77.8% low MDR1 expressers achieved complete remission (CR; p = 0.029). Idarubicin yielded a higher CR rate than daunorubicin in high MDR1 expressers (82.1 vs 41.2%; p = 0.001), it also demonstrated a higher CR rate than daunorubicin (p < 0.05) in high MDR1 expressers exhibiting favorable or intermediate risk, while there was no difference between the two treatment arms in low MDR1 expressers exhibiting either favorable or intermediate risk.
CONCLUSION: Idarubicin is associated with better remission induction of de novo acute myeloid leukemia patients with high MDR1 expression.
Pengcheng Shi; Jie Zha; Xutao Guo; Feili Chen; Zhiping Fan; Fen Huang; Fanyi Meng; Xiaoli Liu; Ru Feng; Bing Xu
Related Documents :
12150135 - Simultaneous detection of receptor mrna and ligand protein in human skin tissues.
20972965 - Northern blot analysis of rna.
1930185 - Quantitation of glut1 and glut4 mrna using a solution hybridization assay.
22659625 - Sirna against plasminogen activator inhibitor-1 ameliorates bleomycin-induced lung fibr...
22347845 - Activating transcription factor 3 and the nervous system.
10319325 - Early growth response protein 1 binds to the luteinizing hormone-beta promoter and medi...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Pharmacogenomics     Volume:  14     ISSN:  1744-8042     ISO Abbreviation:  Pharmacogenomics     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2012-12-20     Completed Date:  2013-09-03     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  100897350     Medline TA:  Pharmacogenomics     Country:  England    
Other Details:
Languages:  eng     Pagination:  17-23     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use*
Bone Marrow Cells / drug effects,  metabolism
Cytarabine / administration & dosage,  adverse effects
Daunorubicin / administration & dosage,  adverse effects
Idarubicin / administration & dosage,  adverse effects
Leukemia, Myeloid, Acute / drug therapy*,  genetics*,  metabolism,  pathology
P-Glycoprotein / biosynthesis*,  genetics*,  metabolism
RNA, Messenger / genetics,  metabolism
Remission Induction / methods
Retrospective Studies
Reg. No./Substance:
0/ABCB1 protein, human; 0/P-Glycoprotein; 0/RNA, Messenger; 04079A1RDZ/Cytarabine; ZRP63D75JW/Idarubicin; ZS7284E0ZP/Daunorubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Does Left Atrial Appendage Closure with a Cardiac Plug System Reduce the Stroke Risk in Nonvalvular ...
Next Document:  Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in C...